AGP Executive Report
Last update: 6 hours agoPharma Deal: SERB Pharmaceuticals has completed its acquisition of exclusive EU/UK/Switzerland/Liechtenstein and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma, aiming to expand access after the EMA post-authorization study obligation was fulfilled. Wealthtech Expansion: Objectway bought FNZ’s Swiss private banking technology business (FNZ Switzerland SA, formerly New Access), rebranding it as Objectway Switzerland and boosting its cross-border private banking footprint that includes Liechtenstein. Crypto Regulation in Motion: Bitcoin Suisse secured a MiCAR crypto-asset service provider licence in Liechtenstein, while OpenPayd also gained MiCA authorization for regulated crypto services across the EEA ahead of the July 1 deadline. Rare Disease Breakthrough: Neuren Pharmaceuticals’ Rett syndrome drug DAYBU (trofinetide) won a positive CHMP opinion for EU marketing authorization, with Liechtenstein and other EEA-linked markets in the mix. Digital Economy: Google cut Play Store fees in the EEA/UK, separating its service fee from a new “billing choice” option that lets developers route payments via their own checkout. Public Safety & Climate: A major heatwave warning expanded across Switzerland, raising risks for schools and daily life.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
